MaaT Pharma Advances Microbiome Therapeutics in Oncology
MaaT Pharma, under the leadership of its CEO and co-founder, has emerged as a frontrunner in the development of microbiome-based therapies, particularly in the field of oncology. The company boasts two full-ecosystem microbiome therapies in clinical development and one in preclinical development, with approximately 300 patients treated across three indications to date.
MaaT013, the company's lead product, is a pooled-donor standardized microbiome ecosystem therapy designed for acute hospital use in patients with GI-aGvHD. The treatment involves three doses over two weeks, administered via an enema bag for direct delivery into the colon. Currently in phase 3 trials, MaaT013 has shown a favorable benefit-risk profile, with high efficacy and low toxicity in patients unresponsive to standard treatments. The positive outcomes from the Early Access Program (EAP) presented at the 2023 American Society of Hematology (ASH) Annual Meeting underscore the potential of MaaT013 in advancing the treatment landscape for aGvHD.
Looking ahead, MaaT Pharma is also investigating MaaT013 in a phase 2 trial for metastatic melanoma, aiming to improve the response to immune checkpoint inhibitor (ICI) therapies through modulation of the gut microbiome. This research highlights the promising role of microbiome diversity in enhancing cancer treatment outcomes.
MaaT033, the company's second candidate, is currently in phase 2b trials as an adjunctive therapy to enhance overall survival in HSCT and cellular therapy recipients. This international, multi-center trial represents the largest randomized controlled study of a microbiome-based therapy in oncology, aiming to optimize microbiota function for a broader patient population in a chronic setting.
MaaT Pharma's commitment to developing innovative therapies for patients with high unmet medical needs is evident in its rapid progress and the inauguration of a GMP manufacturing facility in partnership with Skyepharma. This facility supports the company's clinical production, R&D, and future commercial production, marking a significant step forward in the accessibility of microbiome-based cancer treatments.